• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » BloodCenter of Wisconsin launches next-generation sequencing HemeOnc Panel

BloodCenter of Wisconsin launches next-generation sequencing HemeOnc Panel

October 30, 2014
CenterWatch Staff

BloodCenter of Wisconsin's Diagnostic Laboratories has announced the availability of a comprehensive cancer mutation HemeOnc Panel using next-generation sequencing (NGS) technology. The NGS panel is designed to detect variants in 30 genes that are either prognostic or diagnostic for 10 different myeloid hematologic malignancies.

"NGS technology is revolutionizing how genetic information is utilized for optimal cancer patient care," said Matthew Anderson, M.D., Ph.D., medical director for BloodCenter of Wisconsin's Diagnostic Laboratories. "With NGS we can sequence millions of fragments of tumor DNA simultaneously, providing more comprehensive information to physicians more rapidly, at a lower cost."

BloodCenter's NGS HemeOnc panel interrogates more regions of the genome, focusing on targets that are relevant to particular cancers.

"Using NGS technology, BloodCenter can use one assay to detect the genetic changes in 30 gene targets that may be present in a patient's tumor," said D.P. Dash, Ph.D., director of BloodCenter of Wisconsin's Molecular Oncology Laboratory. "Our primary focus is on hematologic malignancies such as acute myeloid leukemia (AML), myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPN). The panel provides oncologists and pathologists comprehensive information that can support diagnosis, prognosis and risk stratification, and may support the use of targeted therapy."

As part of the diagnostic report, BloodCenter of Wisconsin also will provide additional clinical data which can assist physicians in providing more personalized patient treatment. The enhanced report includes information on FDA approved therapies and relevant clinical trials that can be critical for optimal patient care.

"Physicians need that information to more efficiently manage their patients," said Anderson. "From a physician's perspective, it is a tremendous value to have not only the mutational status of the tumor, but all the relevant clinical data contained in a single report."

BloodCenter's Diagnostic Laboratories help physicians provide clinical care to patients worldwide, fostering better understanding and treatment options for patients with difficult-to-diagnose diseases. In addition, the laboratories collaborate with other institutions and industry partners to bring new diagnostic testing and treatment options to patient care.

Upcoming Events

  • 25Apr

    Effective Root Cause Analysis and CAPA Investigations for Drugs, Devices and Clinical Trials

  • 26Apr

    FDA’s New Laws and Regulations: What Drug and Biologics Manufacturers Need to Know

  • 27Apr

    Califf’s FDA, 2023 and Beyond: Key Developments, Insights and Analysis

  • 17May

    2023 WCG Avoca Quality Consortium Summit

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • tablet

    Digital Intake Platforms Effective as Source of Trial Information, Survey Shows

  • Diversity-360x240.png

    Site Spotlight: EmVenio Research Takes to the Road to Promote Trial Diversity

  • Five Ws

    Consider the Five ‘W’s to Understand Potential Participants

  • QandA-360x240.png

    Perspectives from Smaller-Sized CROs: Q&A with Cheryle Evans

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing